Gyroscope Therapeutics Information

Contact top employees from Gyroscope Therapeutics

Summary

About Gyroscope Therapeutics, a Novartis company:

Gyroscope Therapeutics is a clinical-stage gene therapy company developing gene therapy beyond rare disease to treat diseases of the eye ...Show more

Organization Website

gyroscopetx.com

Social Links

linkedIntwitter

Industries

Headquarters Location

11-21 Northdown Street, London, England, N19BN GB

Employees Size

100-200 employees

Specialties

Gene Therapy, Ophthalmology, Complement, Surgical Device

Founded

2016

Competitors

Founded
Type
Employees
Revenue
Funding
2015Privately
Held
25 - 100 26.2M $223.2M
2007Public
Company
25 - 100 15M $210.9M
2015Privately
Held
25 - 100 7M $173.5M
2017Privately
Held
1-10 - $-

Employees Turnover 4 quarter 2025

Number of employees switched from or switched to
arrow
Total number all of employee turnover
Length of Employment
arrow
Employee tenure at Gyroscope Therapeutics shows a diverse range of experience levels:
5% for 1–2 years14% for 3–4 years62% for 5–7 years19% for 8–10 years
Ex-employees positions
In Company
In New Company
Contact top employees from Gyroscope Therapeutics

FAQ

Gyroscope Therapeutics operates in the Biotech industries. More details can be found on the official website: gyroscopetx.com.
The headquarters of Gyroscope Therapeutics are located in London, United Kingdom.
Gyroscope Therapeutics currently employs 100-200 people.
Well-known competitors of Gyroscope Therapeutics include Harpoon Therapeutics, Regulus Therapeutics, Ribon Therapeutics and Pathios Therapeutics.

Data Privacy

GDPR Icon

GDPR COMPLIANT

SignalHire complies with the General Data Protection Regulation (GDPR). SignalHire follows GDPR requirements, including but not limited to rights of data subjects to access, correct, or delete their personal information and supports the right to be forgotten.

CCPA Icon

CCPA COMPLIANT

SignalHire is CCPA-compliant and provides California residents the right to know, access, opt out, and request deletion of their personal data.

BACK TO TOP